Literature DB >> 26650148

Clostridium difficile Infection: A Rarity in Patients Receiving Chronic Antibiotic Treatment for Crohn's Disease.

Abhik Roy1, Simon Lichtiger.   

Abstract

BACKGROUND: Prolonged antibiotic use is limited by several adverse effects, one of which is Clostridium difficile infection (CDI). The aim of this study was to determine the incidence of CDI in patients receiving chronic antibiotic treatment for Crohn's disease (CD).
METHODS: We conducted a retrospective review of 100 patients with CD for which ≥6 months of outpatient antibiotic therapy was prescribed. Data were collected regarding demographics, CD phenotype, treatment history, and CDI. The incidence of CDI in our patient population was calculated and compared with historical controls.
RESULTS: 100 patients were studied-60% of men, mean age 23.9 years at CD diagnosis. Eighty-two percent had disease involving the ileum, and 33% had disease involving the colon. The mean duration of antibiotic therapy was 39.6 months (range, 6-217 months). The most commonly prescribed classes of antibiotics were fluoroquinolones (84%), penicillins (57%), and cephalosporins (32%). Forty-nine percent of patients were treated with concomitant thiopurines, 45% with budesonide, and 41% with biologics. The overall incidence of CDI was 2%. This incidence of CDI was lower than previously reported for non-CD patients receiving chronic antibiotics for continuous-flow left ventricular assist device infections (12.5%) and orthopedic prosthesis infections (22.2%).
CONCLUSIONS: The incidence of CDI is rare in patients receiving chronic antibiotic treatment for CD, and it seems significantly lower than for non-CD populations reported in the literature.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26650148      PMCID: PMC4882603          DOI: 10.1097/MIB.0000000000000641

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  44 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

2.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management.

Authors:  A Dignass; G Van Assche; J O Lindsay; M Lémann; J Söderholm; J F Colombel; S Danese; A D'Hoore; M Gassull; F Gomollón; D W Hommes; P Michetti; C O'Morain; T Oresland; A Windsor; E F Stange; S P L Travis
Journal:  J Crohns Colitis       Date:  2010-01-15       Impact factor: 9.071

3.  Reduced Paneth cell alpha-defensins in ileal Crohn's disease.

Authors:  Jan Wehkamp; Nita H Salzman; Edith Porter; Sabine Nuding; Michael Weichenthal; Robert E Petras; Bo Shen; Elke Schaeffeler; Matthias Schwab; Rose Linzmeier; Ryan W Feathers; Hiutung Chu; Heriberto Lima; Klaus Fellermann; Tomas Ganz; Eduard F Stange; Charles L Bevins
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-05       Impact factor: 11.205

4.  Mucosal flora in inflammatory bowel disease.

Authors:  Alexander Swidsinski; Axel Ladhoff; Annelie Pernthaler; Sonja Swidsinski; Vera Loening-Baucke; Marianne Ortner; Jutta Weber; Uwe Hoffmann; Stefan Schreiber; Manfred Dietel; Herbert Lochs
Journal:  Gastroenterology       Date:  2002-01       Impact factor: 22.682

5.  Epidemiology of Clostridium difficile colitis in hospitalized patients with inflammatory bowel diseases.

Authors:  Rocco Ricciardi; James W Ogilvie; Patricia L Roberts; Peter W Marcello; Thomas W Concannon; Nancy N Baxter
Journal:  Dis Colon Rectum       Date:  2009-01       Impact factor: 4.585

6.  Kinetics of primary bile acids in patients with non-operated Crohn's disease.

Authors:  P Rutgeerts; Y Ghoos; G Vantrappen
Journal:  Eur J Clin Invest       Date:  1982-04       Impact factor: 4.686

7.  Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection.

Authors:  Daniela Jodorkovsky; Yuki Young; Maria T Abreu
Journal:  Dig Dis Sci       Date:  2009-03-03       Impact factor: 3.199

8.  Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation.

Authors:  Dionysios A Antonopoulos; Susan M Huse; Hilary G Morrison; Thomas M Schmidt; Mitchell L Sogin; Vincent B Young
Journal:  Infect Immun       Date:  2009-03-23       Impact factor: 3.441

9.  Clostridium difficile Infection and Inflammatory Bowel Disease: A Review.

Authors:  Preetika Sinh; Terrence A Barrett; Laura Yun
Journal:  Gastroenterol Res Pract       Date:  2011-09-12       Impact factor: 2.260

10.  Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile.

Authors:  Charlie G Buffie; Vanni Bucci; Richard R Stein; Peter T McKenney; Lilan Ling; Asia Gobourne; Daniel No; Hui Liu; Melissa Kinnebrew; Agnes Viale; Eric Littmann; Marcel R M van den Brink; Robert R Jenq; Ying Taur; Chris Sander; Justin R Cross; Nora C Toussaint; Joao B Xavier; Eric G Pamer
Journal:  Nature       Date:  2014-10-22       Impact factor: 49.962

View more
  4 in total

Review 1.  Management of inflammatory bowel disease with Clostridium difficile infection.

Authors:  Julie D'Aoust; Robert Battat; Talat Bessissow
Journal:  World J Gastroenterol       Date:  2017-07-21       Impact factor: 5.742

2.  Effects of glucocorticoids combined with probiotics in treating Crohn's disease on inflammatory factors and intestinal microflora.

Authors:  Hui Su; Qian Kang; Haihong Wang; Hui Yin; Linghui Duan; Yuli Liu; Ruying Fan
Journal:  Exp Ther Med       Date:  2018-08-02       Impact factor: 2.447

Review 3.  The role of gastrointestinal pathogens in inflammatory bowel disease: a systematic review.

Authors:  Jordan E Axelrad; Ken H Cadwell; Jean-Frederic Colombel; Shailja C Shah
Journal:  Therap Adv Gastroenterol       Date:  2021-03-31       Impact factor: 4.409

4.  Is Clostridium difficile infection a real threat in patients with ulcerative colitis? A prospective, multicenter study in Korea.

Authors:  Dae Bum Kim; Kang-Moon Lee; Sang Hyoung Park; You Sun Kim; Eun Soo Kim; Jun Lee; Sung-Ae Jung; Geom Seog Seo; Ji Min Lee
Journal:  Intest Res       Date:  2018-04-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.